A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2017
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SARAH
- 04 Mar 2015 Results are expected in late 2016, according to a media release.
- 04 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to a media release.
- 24 Jun 2013 To date, 150 patients have been enrolled, according to a media release.